Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 9/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3387930 | 0.95 | TDP1 (0.48) | TDP1DRD2MAOAMAOBCA12 | |
| SCHEMBL31044499 | 0.80 | DRD2 (0.47) | TDP1DRD2MAOAMAOBMEN1 | |
| SCHEMBL3524057 | 0.79 | DRD2 (0.66) | TDP1DRD2MAOAMAOBCA12 | |
| SCHEMBL23034881 | 0.79 | TDP1 (0.49) | TDP1DRD2MAOAMAOBKMT2A | |
| SCHEMBL25774435 | 0.78 | MEN1 (0.53) | DRD2CA12CA2CA9MEN1 | |
| SCHEMBL21389416 | 0.77 | DRD2 (0.44) | TDP1DRD2MEN1GAAKMT2A | |
| SCHEMBL4572542 | 0.76 | DRD2 (0.60) | TDP1DRD2MAOAMAOBCA12 | |
| SCHEMBL137629 | 0.76 | TDP1 (0.85) | TDP1DRD2MAOAMAOBCA12 | |
| SCHEMBL5162656 | 0.76 | TDP1 (0.85) | TDP1DRD2MAOAMAOBCA12 | |
| SCHEMBL134329 | 0.76 | TDP1 (0.85) | TDP1DRD2MAOAMAOBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | TDP1 311/4885DRD2 3994/4885MAOA 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.